Keverprazan Hydrochloride

盐酸凯普拉生

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameKeverprazan Hydrochloride
Drug Alias Name盐酸柯诺拉赞Carenoprazan Hydrochloride倍稳H-008KFP-H008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium-transporting ATPase inhibitors
TargetsPotassium-transporting ATPase
Therapy Area/IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[11] 
Global Approved IndicationsDuodenal UlcerEsophagitis, Peptic
Approved Indications in ChinaDuodenal UlcerEsophagitis, Peptic
Original Approved Country/TerritoryMainland China
Original Approved Date2023/02/14
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNanjing Shenzhou Jiamei Pharmaceutical Co LtdJiangsu Carephar Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Carephar Pharmaceutical Co LtdShanghai Fosun Pharmaceutical Industrial Development Co LtdNanjing Shenzhou Jiamei Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[9] 
Inactive IndicationsLymphomaHelicobacter Infections

Other Information

ATC CodeN/A
Related LinksN/A